Text Size
7 studies found for:    blinatumomab

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Active, not recruiting Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
Condition: B-ALL
Intervention: Drug: Blinatumomab
2 Active, not recruiting Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute ALL
Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: Blinatumomab (MT103)
3 Completed Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL
Condition: Non-Hodgkin's Lymphoma, Relapsed
Intervention: Drug: Blinatumomab (MT103)
4 Recruiting Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: blinatumomab
5 Recruiting Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor ALL
Condition: B-cell Acute Lymphoblastic Leukemia
Intervention: Drug: Blinatumomab
6 Recruiting Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: Blinatumomab
7 Recruiting Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Condition: Diffuse Large B-cell Lymphoma
Intervention: Drug: Blinatumomab
To Top

† Indicates status has not been verified in more than two years